Fujian Highton Development (603162.SH) Controlling Shareholder and Actual Controller Pledge Not to Reduce Holdings in the Company Within 2 Years
Highton Development (603162.SH) announced that, based on confidence in the company's future development prospects and recognition of the company's value, and in order to enhance investor confidence and effectively safeguard investor rights and the stability of the capital market, Mr. Zeng Erbin, the company's controlling shareholder and actual controller, has voluntarily undertaken that within 24 months from October 19, 2026 (i.e., from October 19, 2026 to October 18, 2028), he will not reduce the company shares he directly holds through centralized bidding transactions, block trades, or other methods. During the aforementioned undertaking period, if new shares are generated due to capitalization of capital reserve into share capital, distribution of stock dividends, rights issues, or other circumstances, such shares shall also be subject to this non-reduction undertaking.
Fujian Highton Development (603162.SH) announced that, based on confidence in the company's future development prospects and recognition of the company's value, and to enhance investor confidence and effectively safeguard investor rights and the stability of the capital market, Mr. Zeng Erbin, the company's controlling shareholder and actual controller, has voluntarily committed that within 24 months from October 19, 2026 (i.e., from October 19, 2026 to October 18, 2028), he will not reduce his directly held shares in the company through centralized bidding transactions, block trades, or other methods. During the aforementioned commitment period, if new shares are generated due to capitalization of capital reserves, distribution of stock dividends, rights issues, or other circumstances, such shares shall also be subject to this non-reduction commitment.
Related Articles
HENLIUS (02696) H-Drug ESMO 2026 Preview: U.S. Bridging Study to Be Presented Orally, Adding New Evidence for the World's First Anti-PD-1 Monoclonal Antibody in First-Line Lung Cancer Treatment
Tencent Cloud to raise .com domain registration, renewal, and transfer prices.
Tesla, Inc. (TSLA.US) Shareholder Meeting Preview: Musk's Compensation and Director Re-election in Focus, Merger Rumors with SpaceX Heat Up
HENLIUS (02696) H-Drug ESMO 2026 Preview: U.S. Bridging Study to Be Presented Orally, Adding New Evidence for the World's First Anti-PD-1 Monoclonal Antibody in First-Line Lung Cancer Treatment
Tencent Cloud to raise .com domain registration, renewal, and transfer prices.
Tesla, Inc. (TSLA.US) Shareholder Meeting Preview: Musk's Compensation and Director Re-election in Focus, Merger Rumors with SpaceX Heat Up
